How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation

AIMS: Since 2008, KRAS mutation status in exon 2 has been used to predict response to anti-EGFR therapies. Recent evidence has demonstrated that NRAS status is also predictive of response. Several retrospective ‘extended RAS’ analyses have been performed on clinical trial material. Despite this, are...

Descripción completa

Detalles Bibliográficos
Autores principales: Richman, Susan D, Fairley, Jennifer, Butler, Rachel, Deans, Zandra C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256378/
https://www.ncbi.nlm.nih.gov/pubmed/27681846
http://dx.doi.org/10.1136/jclinpath-2016-203822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256378/
https://www.ncbi.nlm.nih.gov/pubmed/27681846
http://dx.doi.org/10.1136/jclinpath-2016-203822

Ejemplares similares